Aurélien Bourdelon

Promoteurs immobiliers, Happywait digitalise le parcours d’achat dans limmobilier neuf de la signature électronique du contrat de réservation à la livraison du bien. - Gagnez du temps en supprimant les taches coûteuses et sans valeur ajoutée liées à l’Administration des ventes et au suivi des acquéreurs jusqu’à la livraison - Simplifiez la relation acquéreurs en dématérialisant les appels de fonds, les choix de matériaux, le chiffrage des options et le suivi des TMA - Augmentez vos ventes par recommandation en améliorant l’expérience d’achat de vos acquéreurs et en générant de la satisfaction grâce à lespace client - Evitez les doubles saisies et optez pour un logiciel ouvert qui sinterconnecte avec votre système dinformation (ERP, CRM,...) Une démo d’Happywait ? Un simple mail à : demo@happywait.com

Founded in 2018, Posos is a MedTech company that has built the worlds most advanced artificial intelligence platform dedicated to medical prescriptions. It seamlessly integrates into a hospital’s electronic medical records, enabling healthcare prescribers to use AI to prescribe in real-time, based on the best recommendations. Co-created by Posos pharmacists and engineers, the platform has received approval from health authorities in France. Its powerful AI assistant speeds up and optimizes the prescribing process, which is currently very time-consuming and approximate within EHR. Posos can drive massive patient and economic impact, as demonstrated by the numerous EU institutions that have already adopted the solution.

Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.

Payplug is the French payment solution designed for merchants, e-merchants of all sizes and fintechs. With our cutting-edge technology platform, our dedicated conversion tools and our unique mastery of the payment chain, we give you the means to strive for, and exceed, your best. Payplug is a team of 400 passionate people dedicated to helping you achieve your greatest ambitions. We currently support 20,000 SMEs, such as Hast and Plante pour tous, as well as large groups such as Maisons du Monde, Veepee and kiwi.com. Payplug has been part of Groupe BPCE since 2017.

We are a team of GENOMIC EXPLORERS dedicated to cure fibrosis. We work hand in hand with populations under strong natural selection pressure (e.g. Amerindians from Brazil, Allurs, Bantous from Uganda, Hans from Wuhan…) to identify GENETIC VARIANTS of susceptibility or resistance to fibrotic diseases. To explore the mechanisms of fibrosis in new depth, we rely on a unique genomic strategy based on medical genetic expertise in fibrosis, local networks of fields experts and state-of-the-art AI. In cooperation with local institutions & KOLs, our experts have analyzed tens of thousands of samples (plasma, blood, saliva, DNA and RNA, medical exams, exogenic factors) and led pioneering genetic research in the fields of infectious, parasitic & metabolic diseases.* Our goal is to build a unique dataset representative of humanity's diversity to bring disease prevention and cure to all communities. * We always collect samples and data hand in hand with local authorities and populations. We follow up on our patients and bring healthcare to the populations who need it the most by maintaining local teams and by coordinating with NGOs and local authorities.

Our Mission : Discover new growth drivers and ensure their sustainability by helping companies harness the potential of their data. Our Approach : Combine a deep understanding of business specificities with Data Science and Software cutting-edge toolbox mastery. Our Team : We build multidisciplinary task forces of Business Experts, Data Scientists, Product Managers, Developers and Devops to assemble end to end solutions and ensure their sustainability. Our Toolbox : We use cloud computing elasticity, state-of-the-art Scientific Programming and modern Data Visualization to assemble tailored Data Apps. Our Data Apps deliver real-time business insights produced by complex algorithmic cores and display them through ultra-modern interfaces with strong UX/UI. Our Clients scale out from large international corporations like Nestlé, Hermès, Thales, Eiffage, or Saint-Gobain, to mid-cap companies.

ACI partners is a boutique advisory firm committed to deliver, with a hands-on approach, high quality and operational solutions to Top Executives and their teams. Our team can deliver on : • Strategic thinking and operational implementation • Business plan / case and PMI • Advising Board members and C-suite, more specifically CFO, CRO, COO, CIO either globally or on governance to align regulation and operations • Improving operational efficiencies • Business process in/outsourcing • Compliance and permanent control topics • Project management • Change management • Blueprint • Restructuring, Run-Off • Audit and/or remediation plans • Data governance, AI and blockchain Our team is highly skilled and the 3 founding partners complement each-others with deep experiences as consultants and as holders of operational functions in financial industry. We also do regulatory monitoring to keep our knowledge up to date to help our customers navigate an always changing environment, we collaborate with business schools and we help clients with their R&D also thanks to partnerships with highly focused FinTech, AssurTech and RegTech

Promoteurs immobiliers, Happywait digitalise le parcours d’achat dans limmobilier neuf de la signature électronique du contrat de réservation à la livraison du bien. - Gagnez du temps en supprimant les taches coûteuses et sans valeur ajoutée liées à l’Administration des ventes et au suivi des acquéreurs jusqu’à la livraison - Simplifiez la relation acquéreurs en dématérialisant les appels de fonds, les choix de matériaux, le chiffrage des options et le suivi des TMA - Augmentez vos ventes par recommandation en améliorant l’expérience d’achat de vos acquéreurs et en générant de la satisfaction grâce à lespace client - Evitez les doubles saisies et optez pour un logiciel ouvert qui sinterconnecte avec votre système dinformation (ERP, CRM,...) Une démo d’Happywait ? Un simple mail à : demo@happywait.com

Founded in 2018, Posos is a MedTech company that has built the worlds most advanced artificial intelligence platform dedicated to medical prescriptions. It seamlessly integrates into a hospital’s electronic medical records, enabling healthcare prescribers to use AI to prescribe in real-time, based on the best recommendations. Co-created by Posos pharmacists and engineers, the platform has received approval from health authorities in France. Its powerful AI assistant speeds up and optimizes the prescribing process, which is currently very time-consuming and approximate within EHR. Posos can drive massive patient and economic impact, as demonstrated by the numerous EU institutions that have already adopted the solution.

Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.